Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Candin in Head and Neck Cancer to Reduce Recurrence
NCT05952934Phase 2Recruiting
- Sponsor
- University of Arkansas
- Start
- Feb 2024
- Primary completion
- Jul 2032
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 2 trial of candida albicans antigen in head and neck squamous cell carcinoma (HNSCC), sponsored by University of Arkansas. Started Feb 2024; status: recruiting.
02
Drugs
candida albicans antigen
03
Conditions
head and neck squamous cell carcinoma (HNSCC)
Beyond the preview
Go deeper on NCT05952934.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05952934.